Abstract:Antibody drug conjugates (ADCs) are monoclonal antibodies designed to deliver a cytotoxic drug selectively to antigen expressing cells. Several components of an ADC including the selection of the antibody, the linker, the cytotoxic drug payload and the site of attachment used to attach the drug to the antibody are critical to the activity and development of the ADC. The cytotoxic drugs or payloads used to make ADCs are typically conjugated to the antibody through cysteine or lysine residues. This results in ADCs that have a heterogeneous number of drugs per antibody. The number of drugs per antibody commonly referred to as the drug to antibody ratio (DAR), can vary between 0 and 8 drugs for a IgG1 antibody. Antibodies with 0 drugs are ineffective and compete with the ADC for binding to the antigen expressing cells. Antibodies with 8 drugs per antibody have reduced in vivo stability, which may contribute to non target related toxicities. In these studies we incorporated a non-natural amino acid, para acetyl phenylalanine, at two unique sites within an antibody against Her2/neu. We covalently attached a cytotoxic drug to these sites to form an ADC which contains two drugs per antibody. We report the results from the first direct preclinical comparison of a site specific non-natural amino acid anti-Her2 ADC and a cysteine conjugated anti-Her2 ADC. We report that the site specific non-natural amino acid anti-Her2 ADCs have superior in vitro serum stability and preclinical toxicology profile in rats as compared to the cysteine conjugated anti-Her2 ADCs. We also demonstrate that the site specific non-natural amino acid anti-Her2 ADCs maintain their in vitro potency and in vivo efficacy against Her2 expressing human tumor cell lines. Our data suggests that site specific non-natural amino acid ADCs may have a superior therapeutic window than cysteine conjugated ADCs.

Selective Reduction of Cysteine Mutant Antibodies for Site-Specific Antibody-Drug Conjugates

Engineered cysteine antibodies: an improved antibody-drug conjugate platform with a novel mechanism of drug-linker stability

A Genetically Encoded Photocaged Cysteine for Facile Site-Specific Introduction of Conjugation-Ready Thiol Residues in Antibodies

Trisulfide Modification Impacts the Reduction Step in Antibody–Drug Conjugation Process

Redox-Based Reagents for Chemoselective Methionine Bioconjugation

Bridged Cysteine Conjugations

Cysteine-Based Coupling: Challenges and Solutions

Synthesis of site-specific antibody-drug conjugates using unnatural amino acids

Electrocatalytic Reduction of Disulfide Bonds in Antibodies

Production of site-specific antibody–drug conjugates using optimized non-natural amino acids in a cell-free expression system

Site-specific antibody drug conjugates for cancer therapy

Chemo- and regio-selective differential modification of native cysteines on an antibody via the use of dehydroalanine forming reagents

Site-Specific Antibody–Drug Conjugates: The Nexus of Bioorthogonal Chemistry, Protein Engineering, and Drug Development

In vitro and in vivo evaluation of cysteine and site specific conjugated herceptin antibody-drug conjugates

Chemo-selective Modification of Cysteine Residue: Synthesis and Application in the Discovery of Potential Drug Candidates

Construction of homogeneous antibody–drug conjugates using site-selective protein chemistry

Light Chain Q166C Mutation Permits One‐step Site Specific Conjugation on Monoclonal Antibodies

A Versatile Chemo-Enzymatic Conjugation Approach Yields Homogeneous and Highly Potent Antibody-Drug Conjugates.

Self‐Assembled L–DNA Linkers for Rapid Construction of Multi‐Specific Antibody‐Drug Conjugates Library

Antibody conjugation via one and two C-terminal selenocysteines

Selective disulfide reduction for labeling and enhancement of Fab antibody fragments